Who's Who in Massachusetts?

Find out more about Industrial science leaders in Massachusetts: Who they are and how they benefit you.

In the Spotlight

BioSpace and the Massachusetts Biotechnology Council, Inc. Launch 2009 Genetown™ Hotbed Campaign

BioSpace, the leading resource for life science careers and information, and the Massachusetts Biotechnology Council (MBC) unveiled the 10th edition of the Genetown™ Hotbed Campaign this morning.

Massachusetts Life Sciences Center: MLSC Board approves $7.4 million grant for expansion of Organogenesis

The Massachusetts Life Sciences Center Board of Directors has approved a $7.4 million grant to Canton-based Organogenesis, Inc. to facilitate a major expansion that will create hundreds of jobs. The Center will provide $3.7 million this fiscal year, and $3.7 million during FY 2010.

All the Details

Molecular Insight Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. We are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology.

New England BioLabs: NEB - Celebrating over 30 Years of Excellence Established in the mid-1970s as a cooperative laboratory of experienced scientists, New England Biolabs is a world leader in the production and supply of reagents for the life science industry. NEB now offers the largest selection of recombinant and native enzymes for genomic research and continues to expand its product offerings into areas related to proteomics and drug discovery. After more than 30 years, NEB can be considered one of the first companies to help shape today’s biotechnology industry.

ImmunoGen, Inc. was founded in 1981 and became a public company in 1989. From inception, we have focused on the creation of targeted anticancer compounds that make use of monoclonal antibodies to deliver cell-killing agents to cancer cells. Over the years, we have gained unparalleled expertise in the field of immunoconjugates - their design, their development, their preclinical and clinical evaluation, and their manufacturing. To learn more visit

Agencourt Bioscience Corporation: Agencourt's Discovery Solutions suite of genomic and functional genomic services enable biotechnology, pharmaceutical, government and academic research laboratories to develop new and more effective drugs. Our genomic services pipeline sets our facility apart and is based on our patented SPRI technology. Agencourt also offers an array of SPRI-based nucleic acid purification products for customers who wish to improve and automate their own genetic and genomic discovery initiatives. For more information, visit their Web site.